08-18 Acquisition of Own Shares GL
08-12 Acquisition of Own Shares GL
08-12 Tranche Update on Lakefront Biotherapeutics NV's Equity Buyback Plan announced on June 9, 2026. CI
08-11 RBC Adjusts PT on Lakefront Biotherapeutics to $26 From $28, Keeps Sector Perform Rating MT
08-11 Morgan Stanley Adjusts PT on Lakefront Biotherapeutics to $26 From $30, Maintains Equalweight Rating MT
08-11 Lakefront Biotherapeutics H1 Net Profit From Continuing Operations EUR15.8 Mln RE
08-10 Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update GL
08-10 Lakefront Biotherapeutics NV Reports Earnings Results for the Half Year Ended June 30, 2026 CI
08-04 Acquisition of Own Shares GL
07-28 Acquisition of Own Shares GL
07-21 Acquisition of Own Shares GL
07-14 Acquisition of Own Shares GL
07-13 Lakefront Biotherapeutics NV Announces Resignation of Paulo Fontoura as Director CI
07-13 Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi GL
07-07 Acquisition of Own Shares GL
06-30 Acquisition of Own Shares GL
06-29 Lakefront Receives Transparency Notification from Madison Avenue Partners GL
06-23 Acquisition of Own Shares GL
06-17 Lakefront Biotherapeutics NV - Acquisition of Own Shares AQ
06-16 Lakefront Biotherapeutics NV commences an Equity Buyback for 10% of its issued share capital, under the authorization approved on April 28, 2026. CI
06-16 Acquisition of Own Shares GL
06-10 Lakefront Announces Share Buyback Program Zonebourse
06-10 Lakefront Biotherapeutics Kicks Off Up to EUR50 Million Share Buyback Program MT
06-09 Lakefront Biotherapeutics Launches 50 Million Euros Share Repurchase Program MT
06-09 Lakefront Announces Initiation of €50 Million Stock Repurchase Program GL
No results match your criteria